Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advi...( CAMBRIDGE Mass. Jul...)

CAMBRIDGE, Mass., July 27 /PRNewswire/ -- Solace Pharmaceuticals, a private biotechnology company discovering and developing innovative treatments for pain, announced that David Julius, PhD, professor and chair of the department of physiology at the University of California, San Francisco, and a leading pioneer in the pathophysiology of pain, has joined Solace's scientific advisory board.

"We admire Professor Julius' pioneering research in the biology of pain and welcome his participation on Solace's scientific advisory board," said Dr. Eliot Forster, Solace's Chief Executive Officer. "We believe that Professor Julius' scientific interests are complementary to those of Solace, especially with respect to his recent work in glial cells, and we share his dedication to transforming biological insights into opportunities for drug discovery and development. We believe that Professor Julius' expertise will enrich our world-class scientific advisory board and we are pleased to have him join in our mission to discover and develop innovative treatments for pain."

Professor Julius comments, "Solace has staked out some very innovative approaches for targeting and tackling chronic pain. I look forward to working with an extraordinarily talented and diverse group of advisors to bring new ideas to the treatment of pain based on knowledge of its underlying mechanisms."

Professor Julius has made significant discoveries in the molecular basis of somatosensation - the process whereby we experience touch and temperature - and how somatosensation is altered in response to tissue or nerve injury. Professor Julius discovered that capsaicin, the main pungent ingredient in chili peppers, activates an excitatory ion channel, called TRPV1, on sensory nerve endings, and that TRPV1 functions as a molecular integrator of physical and chemical signals that regulate sensory neuron excitability under b
'/>"/>